READ MORE WEDNESDAY, Nov. 28, 2018 (HealthDay News) — Truxima ( rituximab -abbs) has been approved by the U.S. Food and Drug Administration as the first biosimilar to the non-Hodgkin’s lymphoma drug Rituxan , the agency said Wednesday. A biosimilar is a biological product that is approved based on data showing it is “highly similar” to a drug already approved by the FDA, with no “clinically meaningful differences in terms of safety, purity and potency,” the agency said in a news release. Truxima, as with Rituxan, is approved to treat adults with CD20-positive, B-cell non-Hodgkin’s lymphoma . The most common side effects of Truxima are infusion reactions, fever , low blood lymphocytes, chills , infection and weakness . The drug’s label includes a boxed warning that users also may be at increased risk of fatal infusion reactions, severe skin and mouth reactions, reactivation of hepatitis B , and a rare deadly brain infection known as PML. U...
Comments
Post a Comment